Overview

Pancreatic Cancer Market is estimated to register a CAGR of 10.2% during the forecast period 2022 to 2028.

In pancreatic cancer, cancerous cells form in the pancreas. Typically, pancreatic cancer begins in the tissues of your pancreas, which lies behind the lower part of your stomach in your abdomen. In addition to releasing enzymes that aid digestion, your pancreas also produces hormones that help you manage your blood glucose levels. It is possible to develop cancerous or noncancerous tumors in the pancreas. Most pancreatic cancers develop in the cells that line the ducts that carry digestive enzymes out of the pancreas (pancreatic ductal adenocarcinoma). There is a high incidence of pancreatic cancer being detected in its early stages when it is most treatable. Because it often doesn't cause symptoms until other organs have been affected, it is difficult to diagnose. In order to treat pancreatic cancer, treatment options are determined by the extent of the disease. The treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these methods. There is a strong link between alcohol consumption and pancreatic cancer. As a result of a fast-paced lifestyle with little time for decongestion and reconnecting with family, the consumption of supportive substances like these two will rise around the world, and pancreatic cancer incidence will rise as well. The risk for this type of cancer increases with diabetes as well. It is now possible to deal with diabetes complications and end results, including pancreatic cancer, thanks to improved healthcare standards. A better surgical technique and more effective chemotherapeutic agents are available today to treat pancreatic cancer.

Technological advancements in the field of therapeutics, burgeoning incidences of cancer are some key factors that drive the growth of the market.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Pancreatic Cancer Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Pancreatic Cancer Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Pancreatic Cancer Market:
• OncoGenex Pharmaceuticals Inc. (U.S.)
• Pharmacyte Biotech Inc. (U.S.)
• Diffusion Pharmaceuticals (U.S.)
• Oncolytics Biotech (Canada)
• Sun BioPharma, Inc. (U.S.)
• Polaris Pharmaceuticals, Inc. (U.S.)
• Clovis Oncology (U.S.)
• Eli Lilly and Company (U.S.)
• Midatech Pharma PLC (U.K.)
• F. Hoffmann-La Roche AG (Switzerland)
• Celgene Corporation (U.S.)
• Novartis International AG (U.S.)
• Amgen, Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd
• Pfizer, Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

Pancreatic Cancer Market Segmentation:

By Treatment

• Biologic Therapy
• Hormone Therapy
• Chemotherapy
• Targeted Therapy
• Surgery
• Radiation Therapy
• Other Treatments

By Type

• Exocrine Pancreas Cancer
• Endocrine Pancreas Cancer
• Others

By End User

• Research Institute
• Hospitals and Clinics
• Other End Users

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Pancreatic Cancer Market Sample Video:

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the Pancreatic Cancer Market By Treatment, By Type, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Pancreatic Cancer Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Pancreatic Cancer Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Pancreatic Cancer Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Pancreatic Cancer Market, By Treatment Historical Analysis and Forecast 2022-2028 (USD Million)
     7.1. Biologic Therapy
     7.2. Hormone Therapy
     7.3. Chemotherapy
     7.4. Targeted Therapy
     7.5. Surgery
     7.6. Radiation Therapy
     7.7. Other Treatments 

8. Pancreatic Cancer Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million)  
     8.1. Exocrine Pancreas Cancer
     8.2. Endocrine Pancreas Cancer
     8.3. Others

9. Pancreatic Cancer Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)  
     9.1. Research Institute
     9.2. Hospitals and Clinics
     9.3. Other End Users

10. North America Pancreatic Cancer Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Pancreatic Cancer Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Pancreatic Cancer Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Pancreatic Cancer Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    16.1. OncoGenex Pharmaceuticals Inc. (U.S.)
             16.1.1. Company Overview
             16.1.2. Product Portfolio
             16.1.3. SWOT Analysis
             16.1.4. Financial Overview
             16.1.5. Strategic Overview
    16.2. Pharmacyte Biotech Inc. (U.S.)
             16.2.1. Company Overview
             16.2.2. Product Portfolio
             16.2.3. SWOT Analysis
             16.2.4. Financial Overview
             16.2.5. Strategic Overview
    16.3. Diffusion Pharmaceuticals (U.S.)
             16.3.1. Company Overview
             16.3.2. Product Portfolio
             16.3.3. SWOT Analysis
             16.3.4. Financial Overview
             16.3.5. Strategic Overview
    16.4. Oncolytics Biotech (Canada)
             16.4.1. Company Overview
             16.4.2. Product Portfolio
             16.4.3. SWOT Analysis
             16.4.4. Financial Overview
             16.4.5. Strategic Overview
    16.5. Sun BioPharma, Inc. (U.S.)
             16.5.1. Company Overview
             16.5.2. Product Portfolio
             16.5.3. SWOT Analysis
             16.5.4. Financial Overview
             16.5.5. Strategic Overview
    16.6. Polaris Pharmaceuticals, Inc. (U.S.)
             16.6.1. Company Overview
             16.6.2. Product Portfolio
             16.6.3. SWOT Analysis
             16.6.4. Financial Overview
             16.6.5. Strategic Overview
    16.7. Clovis Oncology (U.S.)
             16.7.1. Company Overview
             16.7.2. Product Portfolio
             16.7.3. SWOT Analysis
             16.7.4. Financial Overview
             16.7.5. Strategic Overview
    16.8. Eli Lilly and Company (U.S.)
             16.8.1. Company Overview
             16.8.2. Product Portfolio
             16.8.3. SWOT Analysis
             16.8.4. Financial Overview
             16.8.5. Strategic Overview
    16.9. Midatech Pharma PLC (U.K.)
             16.9.1. Company Overview
             16.9.2. Product Portfolio
             16.9.3. SWOT Analysis
             16.9.4. Financial Overview
             16.9.5. Strategic Overview
    16.10. F. Hoffmann-La Roche AG (Switzerland)
             16.10.1. Company Overview
             16.10.2. Product Portfolio
             16.10.3. SWOT Analysis
             16.10.4. Financial Overview
             16.10.5. Strategic Overview
    16.11. Celgene Corporation (U.S.)
             16.11.1. Company Overview
             16.11.2. Product Portfolio
             16.11.3. SWOT Analysis
             16.11.4. Financial Overview
             16.11.5. Strategic Overview
    16.12. Novartis International AG (U.S.)
             16.12.1. Company Overview
             16.12.2. Product Portfolio
             16.12.3. SWOT Analysis
             16.12.4. Financial Overview
             16.12.5. Strategic Overview
    16.13. Amgen, Inc. (U.S.)
             16.13.1. Company Overview
             16.13.2. Product Portfolio
             16.13.3. SWOT Analysis
             16.13.4. Financial Overview
             16.13.5. Strategic Overview
     16.14. Teva Pharmaceutical Industries Ltd
             16.14.1. Company Overview
             16.14.2. Product Portfolio
             16.14.3. SWOT Analysis
             16.14.4. Financial Overview
             16.14.5. Strategic Overview
     16.15. Pfizer, Inc.
             16.15.1. Company Overview
             16.15.2. Product Portfolio
             16.15.3. SWOT Analysis
             16.15.4. Financial Overview
             16.15.5. Strategic Overview

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures